{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-24-001736","form_type":"8-K","ticker":"LFWD","cik":"0001607962","company_name":"Lifeward Ltd.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.234317+00:00","generated_at":"2026-06-01T23:09:29.025155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ReWalk Robotics Q1 2024 revenue surges 340% to $5.3 million, Medicare reimbursement drives growth","bullets":["Q1 2024 revenue of $5.3 million, up 340% from $1.2 million in Q1 2023.","Medicare payment for ReWalk Personal Exoskeleton established; MACs approve 14 claims since fee schedule.","Net loss widened to $6.3 million ($0.73 per share) from $4.3 million ($0.51 per share) in prior year.","Cash and equivalents of $20.7 million with no debt; full-year 2024 revenue guidance unchanged at $28-$32 million.","Gross margin declined to 26.4% from 46.4%, impacted by AlterG integration and low product volumes."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-24-001736","json":"https://secwatch.observer/filing/0001178913-24-001736.json","markdown":"https://secwatch.observer/filing/0001178913-24-001736.md","text":"https://secwatch.observer/filing/0001178913-24-001736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607962/000117891324001736/0001178913-24-001736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607962/000117891324001736/zk2431465.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:09:29.025155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eba2d94927ad0d5817e282f9382b40f30c9da4f4","claim":"Lifeward Ltd. reported the three months ended March 31, 2024 results: revenue $5.3 million, net income Net loss was $6.3 million, or $0.73 per share, EPS $0.73 per share. Guidance reaffirmed.","evidence_excerpt":"MACs will enable us to further our mission of broader access to innovative exoskeleton technology for appropriate individuals.” First Quarter 2024 Financial Results Revenue was $5.3 million in the first quarter of 2024, compared to $1.2 million during the first quarter of 2023, up $4.1 million, or 340%. Revenue from the sale of products from the former ReWalk","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891324001736/0001178913-24-001736-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$5.3 million"},{"label":"Net income","value":"Net loss was $6.3 million, or $0.73 per share"},{"label":"EPS","value":"$0.73 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}